Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOCLEAR-80 vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits phosphodiesterase, increasing c AMP levels, leading to bronchodilation and reduced airway inflammation.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of asthma,Management of chronic obstructive pulmonary disease (COPD)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Oral: 400-800 mg every 6-8 hours; extended-release formulation given every 12 hours. Target serum concentration 10-20 mcg/m L.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
3–8 hours in adults (mean ~5 h); prolonged in heart failure, liver disease, and COPD; decreased in smokers (4–5 h) and children.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2 and to a lesser extent CYP3A4.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal: approximately 10% unchanged; hepatic metabolism accounts for ~90% of elimination; metabolites excreted in urine.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40% bound, primarily to albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.3–0.7 L/kg (mean 0.45 L/kg); approximates total body water.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 96–100% (immediate-release); food may affect rate but not extent.
Oral: 40-50%; Inhalation: 20-30%
GFR <30 m L/min: reduce dose by 50% and monitor serum levels. GFR 30-50 m L/min: reduce dose by 25%.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class B or C: reduce dose by 50% and monitor levels; contraindicated in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Weight-based: 5-10 mg/kg/dose every 6 hours; maximum 300 mg/day for infants <1 year, 600 mg/day for children 1-9 years, 800 mg/day for adolescents.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lowest effective dose; monitor serum levels closely due to reduced clearance; maximum 400 mg/day initially, titrate slowly.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Monitor serum theophylline levels due to narrow therapeutic index; risk of toxicity with concurrent medications or conditions affecting metabolism.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline, active seizure disorder, uncontrolled arrhythmias.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, chocolate, cola). Charcoal-broiled foods may reduce theophylline absorption. High-protein, low-carbohydrate diets may alter clearance. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline (THEOCLEAR-80) is FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies show increased fetal resorptions and delayed skeletal ossification at high doses. Second and third trimesters: possible increased risk of fetal tachycardia and jitteriness due to placental transfer; neonatal theophylline levels approximate maternal levels. Avoid use unless clearly needed.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline excreted into breast milk; milk-to-plasma ratio approximately 0.7. Peak milk levels occur 1-2 hours after dose. Reported infant adverse effects include irritability and jitteriness. Weigh risks vs benefits; monitor infant for signs of theophylline toxicity. Avoid if infant has compromised cardiovascular status.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy reduces theophylline clearance due to decreased hepatic metabolism and increased volume of distribution, especially in third trimester. Dose adjustments may be required: target serum levels 5-12 mcg/m L. Consider a 20-30% dose reduction in third trimester; monitor levels frequently. Postpartum clearance returns to prepregnancy levels within 2-4 weeks, necessitating dose increase.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Theophylline (THEOCLEAR-80) has a narrow therapeutic index (10-20 mcg/m L). Monitor serum levels closely, especially in patients with hepatic impairment, heart failure, or those on drugs that alter its metabolism (e.g., ciprofloxacin, cimetidine, fluvoxamine). Smoking induces metabolism, requiring higher doses. Do not crush or chew extended-release tablets.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take this medication exactly as prescribed, usually every 12 hours for extended-release forms.,Do not crush, chew, or break the tablets; swallow them whole.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Notify your doctor if you experience nausea, vomiting, insomnia, palpitations, or seizures.,Do not stop taking this medicine abruptly without consulting your doctor.,Keep a consistent schedule and do not change brands or formulations without medical advice.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOCLEAR-80 vs AEROLATE III, answered by our medical review team.
THEOCLEAR-80 is a Bronchodilator that works by Inhibits phosphodiesterase, increasing c AMP levels, leading to bronchodilation and reduced airway inflammation.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOCLEAR-80 and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOCLEAR-80 is: Oral: 400-800 mg every 6-8 hours; extended-release formulation given every 12 hours. Target serum concentration 10-20 mcg/m L.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOCLEAR-80 and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOCLEAR-80 is classified as Category C. Theophylline (THEOCLEAR-80) is FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies show increased fetal resorptions and delayed skeletal ossifi. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.